Forte Biosciences, Inc. (FBRX) Equity Average (2017 - 2020)
Forte Biosciences (FBRX) has disclosed Equity Average for 4 consecutive years, with $22.6 million as the latest value for Q3 2020.
- On a quarterly basis, Equity Average rose 881.41% to $22.6 million in Q3 2020 year-over-year; TTM through Sep 2020 was $22.6 million, a 881.41% increase, with the full-year FY2019 number at -$2.8 million, down 107.83% from a year prior.
- Equity Average was $22.6 million for Q3 2020 at Forte Biosciences, up from $9.1 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $84.3 million in Q3 2017 to a low of -$128.7 million in Q1 2017.
- A 4-year average of $14.2 million and a median of $9.1 million in 2020 define the central range for Equity Average.
- Biggest YoY gain for Equity Average was 881.41% in 2020; the steepest drop was 334.69% in 2020.
- Forte Biosciences' Equity Average stood at $75.6 million in 2017, then plummeted by 68.96% to $23.5 million in 2018, then plummeted by 117.06% to -$4.0 million in 2019, then skyrocketed by 664.61% to $22.6 million in 2020.
- Per Business Quant, the three most recent readings for FBRX's Equity Average are $22.6 million (Q3 2020), $9.1 million (Q2 2020), and -$5.8 million (Q1 2020).